Clinical trials: Heart Failure，Congestive
Heart Failure
Quadripolar Pacing Post Approval Study
The purpose of this post-approval study is to evaluate the acute and chronic performance of a Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy (CRT).
- Trial name
- Quad PAS (NCT01555619)
- Testing
- CRT-D System
- Where
- 71 sites in United States
- Volunteers
- 1,971 people
- Sponsor
- Abbott Medical Devices
Dyspnea, Acute Heart Failure Syndrome
Precision of IMED-4 Lung Fluid Measurements
The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary congestion.
- Conditions
- Dyspnea, Acute Heart Failure Syndrome, Pulmonary Congestion
- Trial name
- NCT02187770
- Testing
- IMED-4
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Intersection Medical, Inc.
Chronic Heart Failure
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects
A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects
- Trial name
- NCT07476157
- Testing
- AD-118, AD-1181
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Heart Failure
Treating Heart Failure With hiPSC-CMs
Heart failure has a high morbidity and mortality because the heart is one of the least regenerative organs in the human body. Drug treatments for heart failure manage symptoms but do not restore lost myocytes.
- Trial name
- NCT05223894
- Testing
- hiPSC-CM therapy, Control
- Where
- China
- Volunteers
- 20 people
- Sponsor
- HELP Therapeutics Co., Ltd.
Heart Failure
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
The purpose of this study was to evaluate long-term safety and tolerability and to provide post-trial access to sacubitril/valsartan to eligible participants who successfully completed CLCZ696B2319 (PANORAMA-HF) core study Part 2…
- Trial name
- NCT03785405
- Testing
- sacubitril/valsartan
- Where
- 79 sites in United States, Argentina and 25 more
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Iron-deficiency
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study
The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced…
- Trial name
- HEART-FID (NCT03037931)
- Testing
- Ferric Carboxymaltose
- Where
- 345 sites in United States, Australia and 11 more
- Volunteers
- 3,065 people
- Sponsor
- American Regent, Inc.
Acute Heart Failure
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE 1 (NCT01065077)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 59 sites in United States, Austria and 15 more
- Volunteers
- 12 people
- Sponsor
- Bayer
Heart Failure
A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)
This multi-center, prospective, non-randomized, single-arm trial will investigate the safety and performance of the HeartWare® Miniaturized Ventricular Assist Device (MVAD®) system over 24 months in subjects with advanced heart…
- Trial name
- NCT01831544
- Testing
- HeartWare MVAD® System
- Where
- 11 sites in Australia, Austria and 3 more
- Volunteers
- 11 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Patients, Heart Failure
National Survey on Coronary Patients and Heart Failure Performed in 2 Patient Groups
The purpose of this observational study is to compare frequency of attainment control goals through the more represented cardiovascular factor risk, dyslipidemia, among coronary patients with or without heart failure in…
- Trial name
- COMPAR (NCT00699959)
- Where
- 324 sites in France
- Volunteers
- 1,650 people
- Sponsor
- AstraZeneca
Heart Failure
A Study on Disease Awareness and Treatment Compliance of Heart Failure Patients
The AWARENESS HF-PD is a cross-sectional, multicenter, survey-based study. Cases who were admitted to the outpatient clinic and hospitalized with the diagnosis of Heart Failure (Acute and Chronic) will be included in the study.
- Trial name
- AWARENESS-HF (NCT05180396)
- Testing
- Questionnaires
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- AstraZeneca Turkey
Heart Failure
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body.
- Trial name
- NCT04722562
- Testing
- Vericiguat (BAY1021189)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Heart Failure
BeneMACS Study:HeartMate 2 (HM2)Left Ventricular Assist Device (LVAD) Survival in Non Transplant Patients is Equal/Better Than Results in Medical Literature
Study Purpose The purpose of the BeneMACS Long-Term LVAD Study is to demonstrate that survival in non transplant patients implanted with the HeartMate II LVAD as destination therapy in Belgium and the Netherlands are equivalent…
- Trial name
- BeneMACs (NCT00983190)
- Testing
- Left Ventricular Assist Device (HeartMate II)
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- Abbott Medical Devices
Heart Failure
V-Lap System For Wirelessly Measuring And Monitoring Left Atrial Pressure (LAP) In Patients With Advance CHF
The objective of this study is to evaluate the safety and performance of the V-LAP System in subjects with New York Heart Association (NYHA) functional class II and III HF, irrespective of left ventricular ejection fraction.
- Trial name
- NCT05712824
- Testing
- V-LAP™ SYSTEM
- Where
- 3 sites in Georgia
- Volunteers
- 10 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Acute Decompensated Heart Failure (ADHF)
Evaluation of FlowMod System While Intermittently Partially Occluding Vena Cava Blood Flow in Subjects With ADHF
FLOW-HF will assess the impact of intermittent partial occlusion of the SVC and/or IVC, the cardiac filling pressure and the difference of effects between the two occlusion locations (SVC and IVC) using the FlowMod flow…
- Trial name
- FLOW-HF (NCT07810335)
- Testing
- FlowMod System in subjects with acute decompensated heart failure (ADHF)
- Where
- 4 sites in Georgia, Uzbekistan
- Volunteers
- 30 people
- Sponsor
- FlowMod, Inc.
Aortic Valve Disease, Aortic Stenosis, Severe
Valvosoft Outcomes Registry for Real-World Evidence
The VALvosoft Outcomes Registry for Real-World Evidence (VALOR-PMCF) is a prospective, multicenter, single-arm post-market clinical follow-up (PMCF) registry designed to evaluate the long-term safety and effectiveness of the…
- Conditions
- Aortic Valve Disease, Aortic Stenosis, Severe, Aortic Valve Calcification, Ultrasound Therapy
- Trial name
- VALOR-PMCF (NCT07520591)
- Testing
- Valvosoft Treatment
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 200 people
- Sponsor
- Cardiawave SA
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Heart Failure, Heart Diseases
Recognition of Heart Failure With Micro Electro-Mechanical Sensors (REFLECS) FI
In this study the ability of smartphone sensors (accelerometer and gyroscope) to identify patients with heart failure will be studied.
- Conditions
- Heart Failure, Heart Diseases, Cardiovascular Diseases
- Trial name
- REFLECS-FI (NCT04444583)
- Where
- 2 sites in Finland
- Volunteers
- 155 people
- Sponsor
- Precordior Ltd
Heart Failure
QuickOptTM Study - Using the QuickOptTM Method for Timing Cycle Optimization
QuickOptTM optimization method provides a quicker, simpler and reliable alternative to standard echocardiography methods for optimization of sensed AV, paced AV and V-V delays in patients with CRT-P devices
- Trial name
- QuickOpt (NCT00918294)
- Testing
- QuickOpt
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Heart Failure
OptiVol® Care Pathway
Medtronic, Inc. is sponsoring the OptiVol® Care Pathway Study, a prospective, randomized, multi-center, post-market clinical trial in the United States.
- Trial name
- NCT00847288
- Testing
- Monthly Review Arm, Quarterly Review Arm
- Where
- 108 sites in United States
- Volunteers
- 1,682 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Congestive Heart Failure, Renal Impairment
Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients
A study to determine the most appropriate dose of MK7418 in heart failure patients presenting with symptoms of volume overload requiring increased diuretic doses.
- Trial name
- NCT00652782
- Testing
- rolofyline
- Volunteers
- 160 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.